Ingevity Corporation (NGVT)

From the record

Ingevity Corporation's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Ingevity Corporation's 10 filed years say what it did: revenue went from $908 million in fiscal 2016 to $1.2 billion in fiscal 2025, up 2.8% a year; it rose in 5 of 9 years; the deepest fall was 30% from fiscal 2022 to fiscal 2025; net income was positive in 7 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Ingevity Corporation's diluted share count shrank about 2.0% a year, and dividends and buybacks returned about 22% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 10 sales (5 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-02 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Ingevity Corporation lost about 563 cents for every dollar of shareholders' money, and gross profitability: its products earned about 28 cents per dollar of everything the company owns. Leverage: it owed about 98 cents per dollar of assets, and net share issuance: its share count shrank 0.3% over the year (the filed statements).

From the record

Ingevity Corporation's standing among 15 graded names in its industry family: revenue of $1.2 billion in fiscal 2025 ranks in the top 46% by size; a net margin of -14.3% ranks in the bottom 43%; revenue growth of -11.2% a year over the last 3 filed years ranks in the bottom 37% (its annual reports).

From the record

Ingevity Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Li, David H (President & CEO, as filed), filing under that title since 2025-04-08, 1.6 years (bottom 13% of its family); the 18 officers and directors filing in the last fifteen months have been on the record a median of 3.2 years (bottom 32%); 12 officer or director changes were reported on Form 8-K since 2023-11-13, against the 18 people in charge now (bottom 25%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Ingevity Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $78 million against debt of $1.2 billion leaves -65.6% of its assets as net cash, bottom 3% of its family; cash from operations less capital spending is 23.4% of revenue (top 10%); a gross margin of 39.5% (top 12%); research spending of 2.4% of revenue (bottom 41%) (its annual report).

From the record

Ingevity Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew -11.2% a year over the last three filed years against 2.8% over all 10, slowing (bottom 21% of its family); the newest year grew -2.7% (bottom 35%); research spending grew -2.1% a year (top 50%); capital spending grew -26% a year (bottom 12%) (its annual reports). Ingevity Corporation reported 3 lines of business in fiscal 2025: Performance Materials at $607 million (52%), Performance Chemicals at $401 million (34%), Advanced Polymer Technologies at $160 million (14%); 0 of 3 grew against the year before (its annual report).

From the record

Ingevity Corporation's newest year against its own record: revenue of $1.2 billion in fiscal 2025 came in 14.7% above the $1.0 billion its prior three years' pace pointed to (top 37% of its family); net income of $167 million against a prior three-year average of $75 million (top 46%); a net margin of -14.3% against -7.9% before (bottom 46%) (its annual reports).